arrow
N

Nicolas Clémenty

Clinique du Millénaire
H指数:36
被引数:4,381

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of obesity on procedural safety and 1-year outcomes after pulsed-field ablation for atrial fibrillation

肥胖对房颤脉冲场消融术后程序安全性和1年预后的影响

2026-10-290
OAAI
Infection experience and management in the extravascular implantable cardioverter- defibrillator: Retrospective analysis from the Pivotal Trial

经皮植入式心律转复除颤器感染经历与管理:Pivotal试验的回顾性分析

2026-07-090
OA
LB-525395-04 REAL-WORLD EXPERIENCE WITH THE EXTRAVASCULAR ICD THROUGH ONE YEAR FROM THE ENLIGHTEN POST-APPROVAL REGISTRY STUDY

LB-525395-04 ENLIGHTEN 批准后注册研究的实际经验:一年内经皮起搏器植入除颤器的应用

2026-04-160
PRE
Long-term outcomes of subcutaneous implantable cardioverter defibrillators: the French nationwide HONEST study

皮下植入式心律转复除颤器长期结局:法国全国性HONEST研究

2025-12-010
PRE
Countrywide introduction of pulsed field ablation for the treatment of atrial fibrillation: Acute results from the FRANCE-PFA registry

全国范围内脉冲场消融治疗心房颤动的应用:FRANCE-PFA注册研究的急性结果

2025-04-250
OA
A leadless ventricular pacemaker providing atrioventricular synchronous pacing in the real-world setting: 12-Month results from the Micra AV post-approval registry
2024-10-013
OAAI
Recurrences of Atrial Fibrillation Despite Durable Pulmonary Vein Isolation: The PARTY-PVI Study
2023-03-0122
PRE
Efficacy and Safety of an Extravascular Implantable Cardioverter-Defibrillator
2022-10-0666
OA
Outcome of patients with early repolarization pattern and syncope
2022-08-012
OAAI
Practical considerations, indications, and future perspectives for leadless and extravascular cardiac implantable electronic devices: a position paper by EHRA/HRS/LAHRS/APHRS
2022-08-0131
OA
Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility (Apr, 10.1038/s41588-021-01007-6, 2022)
2022-04-263
OA